Learn if You Have a Claim Against Pharmacia Corporation (maker of Bextra)

Some Bextra Users Are Suffering Severe Side Effects Kahn Gauthier Swick is investigating claims against pharmaceutical company Pharmacia on behalf of patients who have been prescribed the painkiller Bextra (valdecoxib) and later suffered side effects such as heart attack, stroke, severe skin reaction, or other adverse effects. Bextra, a COX-2 inhibitor, was approved by the federal Food and Drug Administration (FDA) on November 16, 2001, and was marketed in March, 2002. It can be prescribed for osteoarthritis, adult rheumatoid arthritis, and primary dysmennorhea.
Claimant Information

Are you submitting this information on behalf of yourself?	Yes No
Are you submitting this information on behalf of a family member?	Yes No
If yes, please provide: Name
Age
Relationship
Bextra Use

Date you began taking Bextra
Date you stopped taking Bextra
While you were on bextra, did you suffer from any of the following conditions:

Heart Attack	Yes No
Stroke	Yes No
Blood Clots	Yes No
Deep Vein Thrombosis	Yes No
Pulmonary Embolism	Yes No
Steven's Johnson Syndrome	Yes No
Anaphylactic Reaction	Yes No
Angioedema	Yes No
Severe Skin Reaction	Yes No
If submitting for a family member, Death	Yes No
Please list the dates of the above conditions and describe the extent of your injuries resulting from your use of Bextra.
Are you presently covered by health insurance?	Yes No
Have you previously retained an attorney to represent you in this matter?	Yes No

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

Write-Down by Watson Pharmaceuticals Leads to Stockholder Class Action

A class action has been filed against Watson Pharmaceuticals Inc. (NYSE: WPI) and certain of its officers and directors by stockholders who purchased the company's common stock between November 2, 1999, and November 13, 2001. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Infants Who Were Given E-Ferol Injections Certified as National Class

The class has been certified in an action filed against O'Neal, Jones & Feldman Pharmaceuticals, and Carter-Glogau Laboratories on behalf of all persons who received injections of E-Ferol, a vitamin E supplement later to be found toxic. Persons eligible to take part in the action should contact the attorneys for the class for more information.

OSI Pharmaceuticals Seek $360M in Lost Stock Value

A class action has been filed in the Eastern District Court of New York against OSI Pharmaceuticals, Inc.(NASDAQ: OSIP), a New York based biopharmaceutical company, and certain of its officers and directors by stockholders who purchased the company's common stock between April, 26 2004 and November 18, 2004. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. The stockholders seek to recover compensatory damages for the loss of value of their stock.

IntraBiotics Pharmaceuticals Failed to Disclose Iseganan Failure

Several class actions have been filed against biopharmaceutical company IntraBiotics Pharmaceuticals, Inc., (Nasdaq:IBPI) and certain of its officers and directors by stockholders who purchased the company's common stock between September 5, 2003, and June 22, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Drugstore.com Insiders Sold Stock, Then Announced Downward Turn

Several class actions have been filed against online pharmacy drugstore.com, Inc., (Nasdaq:DSCM) and certain of its officers and directors by stockholders who purchased the company's common stock between January 20, 2004, and June 10, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Yale New Haven Hospital Sued for Not Providing Free Care

A class action has been filed against Yale New Haven Hospitals for failing to provide healthcare services to Connecticut residents regardless of their ability to pay. The lawsuit alleges that Yale has an obligation to provide free or low cost healthcare services because it operates as a non-profit organization and is exempt from federal, state and local taxes.